Effect of acid-suppressive therapy on Helicobacter pylori production of interleukin-8 in the gastric mucosa. 2000

M Yoshinaga, and A Ohtani, and S Tsuruta, and T Kato, and E Higashi, and Y Yamada, and N Harada, and H Nawata
Fukuoka Teishin Hospital, Japan. m-yoshi@winter.try-net.or.jp

BACKGROUND Recent studies have shown that acid-suppressive therapy increases the severity of Helicobacter pylori- associated gastritis in the corpus. OBJECTIVE To evaluate interleukin (IL)-8 production in the gastric corpus mucosa before and during acid-suppressive therapy in H pylori-infected patients. METHODS Ten patients with reflux esophagitis (five H pylori-positive and five H pylori-negative) were treated with omeprazole 20 mg. Serum gastrin concentrations, H pylori colonization density and mucosal IL-8 levels in the corpus were investigated at entry and two weeks after starting therapy. IL-8 levels were measured by ELISA. The organism density was determined, and scored according to area occupied by the bacterial colonies. The presence of H pylori was assessed by rapid urease testing and histological finding of gastric biopsy specimens. RESULTS In H pylori-positive patients, concentrations of IL-8 during therapy significantly exceeded those before therapy (36.2+/-6. 8 versus 18.3+/-3.8 pg/mg protein; P<0.05) without altering H pylori density. In H pylori-negative patients, IL-8 levels were similar before and during therapy (6.1+/-2.7 versus 6.3+/-3.0 pg/mg protein). Concentrations of gastrin during therapy were significantly higher than those before therapy in all patients. CONCLUSIONS The results suggest that acid suppression increases mucosal IL-8 levels in H pylori-infected patients with reflux esophagitis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009853 Omeprazole A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. H 168-68,Omeprazole Magnesium,Omeprazole Sodium,Prilosec,H 168 68,H 16868,Magnesium, Omeprazole,Sodium, Omeprazole
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D004942 Esophagitis, Peptic INFLAMMATION of the ESOPHAGUS that is caused by the reflux of GASTRIC JUICE with contents of the STOMACH and DUODENUM. Esophagitis, Reflux,Esophagitides, Peptic,Esophagitides, Reflux,Peptic Esophagitides,Peptic Esophagitis,Reflux Esophagitides,Reflux Esophagitis
D005260 Female Females
D005753 Gastric Mucosa Lining of the STOMACH, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. The surface cells produce MUCUS that protects the stomach from attack by digestive acid and enzymes. When the epithelium invaginates into the LAMINA PROPRIA at various region of the stomach (CARDIA; GASTRIC FUNDUS; and PYLORUS), different tubular gastric glands are formed. These glands consist of cells that secrete mucus, enzymes, HYDROCHLORIC ACID, or hormones. Cardiac Glands,Gastric Glands,Pyloric Glands,Cardiac Gland,Gastric Gland,Gastric Mucosas,Gland, Cardiac,Gland, Gastric,Gland, Pyloric,Glands, Cardiac,Glands, Gastric,Glands, Pyloric,Mucosa, Gastric,Mucosas, Gastric,Pyloric Gland
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M Yoshinaga, and A Ohtani, and S Tsuruta, and T Kato, and E Higashi, and Y Yamada, and N Harada, and H Nawata
March 2001, Alimentary pharmacology & therapeutics,
M Yoshinaga, and A Ohtani, and S Tsuruta, and T Kato, and E Higashi, and Y Yamada, and N Harada, and H Nawata
October 2007, Cellular microbiology,
M Yoshinaga, and A Ohtani, and S Tsuruta, and T Kato, and E Higashi, and Y Yamada, and N Harada, and H Nawata
October 2005, The American journal of gastroenterology,
M Yoshinaga, and A Ohtani, and S Tsuruta, and T Kato, and E Higashi, and Y Yamada, and N Harada, and H Nawata
December 2013, World journal of gastroenterology,
M Yoshinaga, and A Ohtani, and S Tsuruta, and T Kato, and E Higashi, and Y Yamada, and N Harada, and H Nawata
February 1999, Digestive diseases and sciences,
M Yoshinaga, and A Ohtani, and S Tsuruta, and T Kato, and E Higashi, and Y Yamada, and N Harada, and H Nawata
May 2005, Infection and immunity,
M Yoshinaga, and A Ohtani, and S Tsuruta, and T Kato, and E Higashi, and Y Yamada, and N Harada, and H Nawata
December 2002, Gastroenterology,
M Yoshinaga, and A Ohtani, and S Tsuruta, and T Kato, and E Higashi, and Y Yamada, and N Harada, and H Nawata
September 2006, Journal of gastroenterology and hepatology,
M Yoshinaga, and A Ohtani, and S Tsuruta, and T Kato, and E Higashi, and Y Yamada, and N Harada, and H Nawata
May 2004, Journal of gastroenterology and hepatology,
M Yoshinaga, and A Ohtani, and S Tsuruta, and T Kato, and E Higashi, and Y Yamada, and N Harada, and H Nawata
March 2019, Clinical and translational gastroenterology,
Copied contents to your clipboard!